Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

被引:361
作者
Senderowicz, AM
Headlee, D
Stinson, SF
Lush, RM
Kalil, N
Villalba, L
Hill, K
Steinberg, SM
Figg, WD
Tompkins, A
Arbuck, SG
Sausville, EA
机构
[1] NCI, Dev Therapeut Program, Clin Trials Unit,Med Branch, Biostat & Data Management Sect, Bethesda, MD 20892 USA
[2] NCI, Div Clin Sci & Invest Drug Branch, Canc Treatment Evaluat Program, Bethesda, MD 20892 USA
[3] NCI, Lab Drug Discovery & Dev Res, Dev Therapeut Program, Div Canc Treatment & Diagnosis, Bethesda, MD 20892 USA
关键词
D O I
10.1200/JCO.1998.16.9.2986
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We conducted a phase I trial of the cyclin-dependent kinase inhibitor, flavopiridol (National Service Center [NSC] 649890), to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacology of flavopiridol given as a 72-hour infusion every 2 weeks. Patients and Methods: Seventy-six patients with refractory malignancies with prior disease progression were treated with flavopiridol, with first-cycle pharmacokinetic sampling. Results: Forty-nine patients defined our first MTD, 50 mg/m(2)/d x 3 with dose-limiting toxicity (DLT) of secretory diarrhea at 62.5 mg/kg/d x 3. Subsequent patients received antidiarrheal prophylaxis (ADP) to define a second MTD, 78 mg/m(2)/d x 3 with DLT of hypotension at 98 mg/m(2)/d x 3. Other toxicities included a proinflammatory syndrome with alterations in acute-phase reactants, particularly at doses >50 mg/m(2)/d x 3, which in some patients prevented chronic therapy every 2 weeks. In some patients, ADP wets not successful, requiring dose-deescalation. Although approximately 70% of patients displayed predictable flavopiridol pharmacology, we observed unexpected interpatient variability and postinfusion peaks in approximately 30% of Eases. At the two MTDs, we achieved a mean plasma flavopiridol concentration of 271 nM(50 mg/m(2)/d x 3) and 344 nM (78 mg/m(2)/d x 3), respectively. One partial response in a patient with renal cancer and minor responses (n = 3) in patients with non Hodgkin's lymphoma, colon, and renal cancer occurred. Conclusion: The MTD of infusional flavopiridol is 50 mg/m(2)/d x 3 with dose-limiting secretory diarrhea at 62.5 mg/m(2)/d x 3. With ADP, 78 mg/m(2)/d x 3 was the MTD, with dose-limiting hypotension at 98 mg/m(2)/d x 3. Based on chronic tolerability, 50 mg/m(2)/d x 3 is the recommended phase II dose without ADP. Antitumor effect was observed in certain patients with renal, prostate, and colon cancer, and non-Hodgkin's lymphoma. Concentrations of flavopiridol (200 to 400 nM) needed for cyclin-dependent kinase inhibition in preclinical models were achieved safely.
引用
收藏
页码:2986 / 2999
页数:14
相关论文
共 42 条
  • [1] PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS
    ABIGERGES, D
    CHABOT, GG
    ARMAND, JP
    HERAIT, P
    GOUYETTE, A
    GANDIA, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 210 - 221
  • [2] Arguello F, 1998, BLOOD, V91, P2482
  • [3] Cancer undefeated
    Bailar, JC
    Gornik, HL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (22) : 1569 - 1574
  • [4] THE ACUTE-PHASE RESPONSE
    BAUMANN, H
    GAULDIE, J
    [J]. IMMUNOLOGY TODAY, 1994, 15 (02): : 74 - 80
  • [5] FLAVONE ACETIC-ACID - IS VASCULAR SHUTDOWN THE CRUCIAL MECHANISM OF ACTION
    BIBBY, MC
    DOUBLE, JA
    PHILLIPS, RM
    QUINN, PKM
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1991, 60 (1-2) : 395 - 399
  • [6] Bible KC, 1996, CANCER RES, V56, P4856
  • [7] Bible KC, 1997, CANCER RES, V57, P3375
  • [8] BOLDT DH, 1984, CANCER RES, V44, P4661
  • [9] Carlson BA, 1996, CANCER RES, V56, P2973
  • [10] CORDONCARDO C, 1995, AM J PATHOL, V147, P545